Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries.
Zozaya N, Villaseca J, Fernández I, Abdalla F, Cadenas-Noreña B, Calleja MÁ, Gómez-Pajuelo P, Mestre-Ferrándiz J, Oliva-Moreno J, Trillo JL, Hidalgo-Vega Á. Zozaya N, et al. Among authors: calleja ma. Appl Health Econ Health Policy. 2024 May;22(3):297-313. doi: 10.1007/s40258-023-00867-9. Epub 2024 Jan 12. Appl Health Econ Health Policy. 2024. PMID: 38214848 Review.
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.
Zozaya N, Villaseca J, Abdalla F, Calleja MA, Díez-Martín JL, Estévez J, García-Sanz R, Martínez-López J, Sierra J, Vera R, Hidalgo-Vega A. Zozaya N, et al. Among authors: calleja ma. Clin Transl Oncol. 2022 Jun;24(6):968-980. doi: 10.1007/s12094-021-02757-9. Epub 2022 Jan 8. Clin Transl Oncol. 2022. PMID: 34997475 Free PMC article. Review.
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).
de Andrés-Nogales F, Cruz E, Calleja MÁ, Delgado O, Gorgas MQ, Espín J, Mestre-Ferrándiz J, Palau F, Ancochea A, Arce R, Domínguez-Hernández R, Casado MÁ; FinMHU-MCDA Group. de Andrés-Nogales F, et al. Among authors: calleja ma. Orphanet J Rare Dis. 2021 Apr 26;16(1):186. doi: 10.1186/s13023-021-01809-1. Orphanet J Rare Dis. 2021. PMID: 33902672 Free PMC article.
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Guerra Veloz MF, et al. Among authors: calleja ma. World J Gastroenterol. 2018 Dec 14;24(46):5288-5296. doi: 10.3748/wjg.v24.i46.5288. World J Gastroenterol. 2018. PMID: 30581277 Free PMC article.
Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.
Valdés-Delgado T, Aguado-Paredes A, Merino-Bohórquez V, Martín-Manzanares J, Alonso MM, Maldonado B, Castro L, Belvis M, Benítez B, Caunedo Á, Calleja MÁ, Argüelles-Arias F. Valdés-Delgado T, et al. Among authors: calleja ma. Dig Dis Sci. 2024 Jan;69(1):228-234. doi: 10.1007/s10620-023-08139-1. Epub 2023 Nov 9. Dig Dis Sci. 2024. PMID: 37943382 Free PMC article.
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ, Poveda JL, Rivero A, Serra-Baldrich E, Silvestre JF, Armario-Hita JC, Calleja MÁ, Carrascosa JM, Flórez Á, Herranz P, Comellas M, Ortiz de Frutos FJ. Pereyra-Rodríguez JJ, et al. Among authors: calleja ma. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e59-e62. doi: 10.1111/jdv.19432. Epub 2023 Aug 23. J Eur Acad Dermatol Venereol. 2024. PMID: 37594914 No abstract available.
37 results